{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-002522","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.753494+00:00","generated_at":"2026-05-28T04:48:51.491929+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Carisma Therapeutics receives Nasdaq bid price deficiency notice; has until July 7, 2025 to regain compliance","bullets":["Received Nasdaq notice on Jan 6, 2025 for non-compliance with minimum bid price of $1.00 per share.","Company has 180 days, until July 7, 2025, to regain compliance by having closing bid price ≥$1.00 for 10 consecutive business days.","If compliance not achieved, may transfer to Nasdaq Capital Market for additional 180-day period, subject to meeting other listing standards.","Company intends to monitor bid price and consider options including potential reverse stock split if needed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-002522","json":"https://secwatch.observer/filing/0001104659-25-002522.json","markdown":"https://secwatch.observer/filing/0001104659-25-002522.md","text":"https://secwatch.observer/filing/0001104659-25-002522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925002522/0001104659-25-002522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925002522/tm252702d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:48:51.491929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a763a458d226c4ed60e9fee96fd019e160f0412","claim":"Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).","evidence_excerpt":"January 6, 2025, Carisma Therapeutics Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upo","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465925002522/0001104659-25-002522-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}